Li Cui, Kitzerow Oliver, Nie Fujiao, Dai Jingxuan, Liu Xiaoyan, Carlson Mark A, Casale George P, Pipinos Iraklis I, Li Xiaowei
Mary & Dick Holland Regenerative Medicine Program and Department of Neurological Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, United States.
Department of Genetics Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, United States.
Bioact Mater. 2020 Sep 22;6(3):684-696. doi: 10.1016/j.bioactmat.2020.09.007. eCollection 2021 Mar.
Peripheral arterial disease (PAD) is a progressive atherosclerotic disorder characterized by narrowing and occlusion of arteries supplying the lower extremities. Approximately 200 million people worldwide are affected by PAD. The current standard of operative care is open or endovascular revascularization in which blood flow restoration is the goal. However, many patients are not appropriate candidates for these treatments and are subject to continuous ischemia of their lower limbs. Current research in the therapy of PAD involves developing modalities that induce angiogenesis, but the results of simple cell transplantation or growth factor delivery have been found to be relatively poor mainly due to difficulties in stem cell retention and survival and rapid diffusion and enzymolysis of growth factors following injection of these agents in the affected tissues. Biomaterials, including hydrogels, have the capability to protect stem cells during injection and to support cell survival. Hydrogels can also provide a sustained release of growth factors at the injection site. This review will focus on biomaterial systems currently being investigated as carriers for cell and growth factor delivery, and will also discuss biomaterials as a potential stand-alone method for the treatment of PAD. Finally, the challenges of development and use of biomaterials systems for PAD treatment will be reviewed.
外周动脉疾病(PAD)是一种进行性动脉粥样硬化疾病,其特征是供应下肢的动脉狭窄和闭塞。全球约有2亿人受PAD影响。目前的手术治疗标准是开放或血管腔内血运重建,其目标是恢复血流。然而,许多患者并不适合这些治疗,并且下肢会持续缺血。目前PAD治疗的研究包括开发诱导血管生成的方法,但单纯的细胞移植或生长因子递送的效果相对较差,主要原因是干细胞保留和存活困难,以及在受影响组织中注射这些因子后生长因子的快速扩散和酶解。包括水凝胶在内的生物材料有能力在注射过程中保护干细胞并支持细胞存活。水凝胶还可以在注射部位持续释放生长因子。本综述将重点关注目前作为细胞和生长因子递送载体正在研究的生物材料系统,还将讨论生物材料作为治疗PAD的一种潜在独立方法。最后,将综述用于PAD治疗的生物材料系统开发和使用所面临的挑战。